Friedman Billings Downgrades Progenics Pharma (PGNX) to Underperform
More News related to PGNX
- Progenics Pharma (PGNX) Reports In-Line Q2 Loss of $0.08
- Progenics Pharmaceuticals Reports Second Quarter 2008 Results
- Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
- Friedman Billings Downgrades Progenics Pharma (PGNX) to Underperform
- Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
More News related to Downgrades
- Raymond James Downgrades 8 Restaurant Stocks Today
- Merrill Lynch Downgrades General Dynamics (GD) to Neutral
- Deutshe Bank Downgrades Cavium Networks (CAVM) to Hold
- Sandler O'Neill Downgrades Boston Private (BPFH) to Sell
- Raymond James Downgrades Hibbet Sports (HIBB) to Market Perform
Friedman Billings downgrades Progenics Pharmaceuticals (Nasdaq: PGNX) from Market Perform to Underperform with a $12 price target.
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat debilitating conditions and life-threatening diseases in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
